^
    Apply
    Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer (NRG-LU003) (NCT03737994)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    07/25/2019
    Primary completion :
    07/21/2021
    Completion :
    12/02/2025
    MET
    |
    ALK positive • MET amplification • ALK rearrangement
    |
    cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)
    Post Marketing Surveillance(PMS) Study of Lorviqua in Korea (NCT05599412)
    Phase N/A
    Pfizer
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    05/22/2023
    Primary completion :
    03/31/2028
    Completion :
    03/31/2028
    ALK
    |
    ALK positive
    |
    Lorbrena (lorlatinib)
    Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (NCT03126916)
    Phase 3
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    05/14/2018
    Primary completion :
    09/30/2026
    Completion :
    09/30/2026
    MYCN
    |
    MYCN amplification
    |
    cisplatin • Xalkori (crizotinib) • carboplatin • Lorbrena (lorlatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • Leukine (sargramostim) • captisol-enabled melphalan • cyclophosphamide intravenous • dexrazoxane
    Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC (COMLORLA) (NCT06690541)
    Phase N/A
    Peking University Cancer Hospital & Institute
    Not yet recruiting
    Last update posted :
    11/15/2024
    Initiation :
    11/10/2024
    Primary completion :
    04/30/2027
    Completion :
    10/31/2030
    ALK
    |
    Lorbrena (lorlatinib)
    Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients (ALKALINE) (NCT04127110)
    Phase 2
    European Organisation for Research and Treatmen...
    Active, not recruiting
    Last update posted :
    11/05/2024
    Initiation :
    11/17/2020
    Primary completion :
    07/31/2024
    Completion :
    11/01/2024
    ALK
    |
    ALK rearrangement
    |
    Lorbrena (lorlatinib)
    Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation (PIKACHU) (NCT04322890)
    Phase 2
    Hunan Province Tumor Hospital
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    04/16/2020
    Primary completion :
    12/24/2026
    Completion :
    12/24/2027
    EGFR • BRAF • ALK • ROS1
    |
    EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation
    |
    cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)
    PF-07284892 in Participants With Advanced Solid Tumors (NCT04800822)
    Phase 1
    Pfizer
    Active, not recruiting
    Last update posted :
    04/30/2024
    Initiation :
    03/17/2021
    Primary completion :
    06/18/2024
    Completion :
    11/29/2025
    ALK • ROS1 • NF1
    |
    BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive
    |
    Erbitux (cetuximab) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • Braftovi (encorafenib) • PF-07284892
    Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients (NCT04979988)
    Phase N/A
    Pfizer
    Completed
    Last update posted :
    04/05/2024
    Initiation :
    08/02/2021
    Primary completion :
    12/09/2021
    Completion :
    12/09/2021
    ALK
    |
    ALK rearrangement
    |
    Alecensa (alectinib) • Lorbrena (lorlatinib)
    Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer (NCT04362072)
    Phase 4
    Pfizer
    Active, not recruiting
    Last update posted :
    03/08/2024
    Initiation :
    09/29/2020
    Primary completion :
    06/25/2024
    Completion :
    06/25/2024
    ALK
    |
    ALK rearrangement
    |
    Lorbrena (lorlatinib)
    Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE) (NCT04111705)
    Phase 2
    Intergroupe Francophone de Cancerologie Thoracique
    Active, not recruiting
    Last update posted :
    03/07/2024
    Initiation :
    08/05/2020
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    ALK
    |
    ALK rearrangement
    |
    Lorbrena (lorlatinib)
    A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled (NCT06282991)
    Phase N/A
    Pfizer
    Completed
    Last update posted :
    02/28/2024
    Initiation :
    07/22/2020
    Primary completion :
    01/18/2021
    Completion :
    01/18/2021
    ALK
    |
    Lorbrena (lorlatinib)
    A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China (NCT03909971)
    Phase 2
    Pfizer
    Active, not recruiting
    Last update posted :
    02/21/2024
    Initiation :
    04/28/2019
    Primary completion :
    08/10/2020
    Completion :
    12/31/2024
    EML4
    |
    ALK positive • EML4-ALK fusion • ALK fusion
    |
    Lorbrena (lorlatinib)